ndrome (LGS), a Phase Ill trial in tuberous sclerosis complex, and a Phase II/III trial in infantile spasms. The first three Phase Ill trials (one in Dravet and two in LGS) supported an NDA submission, leading to FDA approval in June 2018. The Phase III efficacy portion of the first Dravet trial randomiz